ABT
ACCE-researchedOverview
ACCE thesis
Abbott manufactures medical devices, diagnostics, nutrition products, and pharmaceuticals across four distinct business segments, with medical devices generating 43% of revenue and diagnostics another 32%. The company dominates continuous glucose monitoring through its FreeStyle Libre system, which commands over 60% global market share and drives double-digit growth in the medical devices segment. Abbott's diabetes care franchise benefits from expanding Type 2 diabetes prevalence and increasing CGM adoption beyond insulin-dependent patients, with management targeting 7 million new users annually. Trading at 14.5x forward earnings despite 7.8% revenue growth, the stock offers compelling value given FreeStyle Libre's recurring revenue model and 56.5% gross margins that provide substantial operating leverage. The recent FDA approval for FreeStyle Libre 2 over-the-counter sales removes prescription barriers and opens a massive addressable market of 25 million pre-diabetic Americans.
- highEarnings decline severeEarnings YoY -19.7% despite revenue growing +7.8%, signaling significant margin or cost pressure compressing profitability.
- moderateOperating margin thinOperating margin at 13.5% is low for a medical device company with 56.5% gross margin, implying heavy SG&A/R&D spend.
- moderateMomentum score very lowACCE Momentum score of 17/100 is notably weak, and QoQ revenue growth is -2.6%, suggesting near-term headwinds.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
Price
Valuation
INVESTORSix independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.
- +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
- +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
- +Editable DCF workbench with saved scenarios
Quality
INVESTORThe full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.
- +Conviction score breakdown and earnings-quality grade
- +Growth / value / quality / momentum component scores
- +90-day score history and score-threshold backtests
Analysts
Wall Street consensus
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
- +Price-target low / average / high vs the current price, with implied upside
- +Forward revenue and EPS consensus by fiscal year
- +ACCE fair-value models lined up against the Street
Smart Money
PROFollow the institutions: 13F position changes, insider trades, and active 13D activist filings.
- +Quarter-over-quarter institutional position changes
- +Recent open-market insider transactions
- +Active 13D activist filings and top holders
Compare
Where it sits vs peers
Algorithmic peers (6)
| Ticker | Company | Mcap | P/E | ROE | D/E | Yield | Quality | |
|---|---|---|---|---|---|---|---|---|
| MDT | Medtronic plc. Ordinary Shares | $117.8B | 22.7 | 10.7% | 0.56 | 3.1% | - | Compare |
| SYK | Stryker Corporation Common Stock | $105.5B | 28.5 | 16.5% | 0.71 | 1.2% | - | Compare |
| BSX | Boston Scientific Corporation Common Stock | $62.8B | 17.5 | 15.3% | 0.47 | 0.0% | - | Compare |
| EW | Edwards Lifesciences Corporation Common Stock | $50.9B | 52.5 | 9.2% | 0.06 | 0.0% | - | Compare |
| SHL.DE | Siemens Healthineers | $48.4B | 19.2 | 12.2% | 0.61 | 2.6% | - | Compare |
| DXCM | DexCom Inc. Common Stock | $33.7B | 35.3 | 38.5% | 0.46 | 0.0% | - | Compare |
Sector report card
Where ABT ranks against its sector peers on each metric.
News and Record
Press releases mentioning this company
- GlobeNewswire•Sep 18, 2026Interventional Cardiology Devices Market by Type, End User - Global Forecast to 2031
- PR Newswire•Sep 17, 2026Abbott declares 411th consecutive quarterly dividend
- GlobeNewswire•Sep 16, 2026Point of Care Diagnostics Market Forecasts Growth from $20.63B (2026) to $31.46B by 2031, Profiling QuidelOrtho, Sysmex, HemoCue, Trinity Biotech & 15 Other Key Players
Ask anything, Pro feature
Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.